At the time of writing, Brainstorm Cell Therapeutics, Inc [BCLI] stock is trading at $1.12, up 14.87%. An important factor to consider is whether the stock is rising or falling in short-term value. The BCLI shares have gain 30.23% over the last week, with a monthly amount drifted -17.04%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Brainstorm Cell Therapeutics, Inc [NASDAQ: BCLI] stock has seen the most recent analyst activity on February 04, 2021, when Maxim Group upgraded its rating to a Buy but kept the price target unchanged to $12 for it. Previously, Maxim Group downgraded its rating to Hold on November 17, 2020. On December 19, 2016, Maxim Group reiterated its Buy rating and revised its price target to $6 on the stock. Maxim Group reiterated its Buy rating and decreased its price target to $5 on December 22, 2015.
For the past year, the stock price of Brainstorm Cell Therapeutics, Inc fluctuated between $0.72 and $10.05. Brainstorm Cell Therapeutics, Inc [NASDAQ: BCLI] shares were valued at $1.12 at the most recent close of the market.
Analyzing the BCLI fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -6.34, Equity is 2.03 and Total Capital is 1.64. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.9767 points at the first support level, and at 0.8333 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.2667, and for the 2nd resistance point, it is at 1.4133.
Ratios To Look Out For
It is important to note that Brainstorm Cell Therapeutics, Inc [NASDAQ:BCLI] has a current ratio of 0.04. On the other hand, the Quick Ratio is 0.04, and the Cash Ratio is 0.02.
Transactions by insiders
Recent insider trading involved Lebovits Chaim, President & CEO, that happened on Oct 01 ’24 when 1836.0 shares were purchased. President & CEO, Lebovits Chaim completed a deal on Sep 30 ’24 to buy 22000.0 shares. Meanwhile, Chief Medical Officer Dagher Ibrahim B. sold 63000.0 shares on Jul 19 ’24.
